Intellia Therapeutics Future Growth
Future criteria checks 2/6
Intellia Therapeutics is forecast to grow earnings and revenue by 33.4% and 58.3% per annum respectively. EPS is expected to grow by 37.6% per annum. Return on equity is forecast to be -15.6% in 3 years.
Key information
33.4%
Earnings growth rate
37.6%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 58.3% |
Future return on equity | -15.6% |
Analyst coverage | Good |
Last updated | 10 Jun 2024 |
Recent future growth updates
Recent updates
Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
Aug 01Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Jul 05Intellia Makes History. Can It Deliver A Cure?
Jun 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 116 | -557 | -426 | -216 | 17 |
12/31/2025 | 59 | -530 | -414 | -355 | 26 |
12/31/2024 | 68 | -489 | -384 | -364 | 28 |
3/31/2024 | 53 | -486 | -418 | -405 | N/A |
12/31/2023 | 36 | -481 | -408 | -394 | N/A |
9/30/2023 | 52 | -462 | -407 | -391 | N/A |
6/30/2023 | 53 | -453 | -384 | -368 | N/A |
3/31/2023 | 53 | -430 | -379 | -363 | N/A |
12/31/2022 | 52 | -474 | -392 | -333 | N/A |
9/30/2022 | 51 | -442 | -355 | -298 | N/A |
6/30/2022 | 45 | -400 | -342 | -285 | N/A |
3/31/2022 | 38 | -369 | -309 | -252 | N/A |
12/31/2021 | 33 | -268 | -238 | -225 | N/A |
9/30/2021 | 27 | -229 | -221 | -211 | N/A |
6/30/2021 | 42 | -185 | -181 | -174 | N/A |
3/31/2021 | 52 | -149 | -69 | -64 | N/A |
12/31/2020 | 58 | -134 | -53 | -50 | N/A |
9/30/2020 | 62 | -120 | -43 | -38 | N/A |
6/30/2020 | 51 | -116 | -41 | -35 | N/A |
3/31/2020 | 46 | -109 | -126 | -120 | N/A |
12/31/2019 | 43 | -100 | -110 | -103 | N/A |
9/30/2019 | 40 | -90 | -89 | -83 | N/A |
6/30/2019 | 37 | -89 | -76 | -70 | N/A |
3/31/2019 | 33 | -86 | -71 | -65 | N/A |
12/31/2018 | 30 | -85 | -68 | -61 | N/A |
9/30/2018 | 29 | -90 | -81 | -74 | N/A |
6/30/2018 | 29 | -83 | -86 | -78 | N/A |
3/31/2018 | 27 | -76 | -79 | -72 | N/A |
12/31/2017 | 26 | -68 | N/A | -65 | N/A |
9/30/2017 | 25 | -54 | N/A | -58 | N/A |
6/30/2017 | 23 | -46 | N/A | -49 | N/A |
3/31/2017 | 21 | -38 | N/A | 34 | N/A |
12/31/2016 | 16 | -32 | N/A | 36 | N/A |
9/30/2016 | 13 | -26 | N/A | 45 | N/A |
6/30/2016 | 9 | -22 | N/A | 49 | N/A |
3/31/2016 | 7 | -18 | N/A | -16 | N/A |
12/31/2015 | 6 | -12 | N/A | -2 | N/A |
9/30/2015 | 4 | -14 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NTLA's revenue (58.3% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: NTLA's revenue (58.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NTLA is forecast to be unprofitable in 3 years.